In the rapidly evolving landscape of MedTech, neuro42, Inc. stands out as a beacon of innovation and patient-centric solutions. Under the visionary leadership of Abhita Batra, co-founder and Chief Strategy Officer, neuro42 is on a mission to transform the way brain imaging and surgical interventions are approached. With a unique blend of portable MRI technology, robotics, and artificial intelligence, the company is poised to set new standards in neurosurgical care. Abhita Batra’s career is a testament to her relentless pursuit of advancing medical technology. A serial entrepreneur and seasoned business strategist, Batra’s impressive resume includes roles as CEO and Director at Otomagnetics, founder and Managing Director of Advanced Biopharma Consulting, and director at Admac Group of Companies. Her experience extends to her previous role as co-founder and COO of Navya, a biotechnology company focused on destroying solid tumors.

Batra’s educational background is equally distinguished, with a Global MBA from UCLA Anderson and NUS and a master’s in Biotechnology with a specialization in Pharmaceutical Sciences from the University of Pennsylvania. Her diverse expertise in fundraising, business development, and commercialization has significantly accelerated research and development timelines, making groundbreaking medical technologies accessible at an unprecedented pace.

neuro42: Pioneering Portable Neuroimaging

neuro42, Inc. is revolutionizing diagnostic imaging and image-guided surgical interventions with its cutting-edge technology. The company is developing a portable MRI, robotic, and AI platform designed for point-of-care imaging and interventions. This innovative approach is backed by over 30 patents and promises to enhance both patient and physician experiences through its novel, easy-to-use configuration.

The need for neuro42’s technology is clear: neurological conditions are on the rise, with around 800,000 strokes, 1.5 million traumatic brain injuries, and countless brain tumors diagnosed annually in the U.S. Traditional MRI systems are often cumbersome and limited in their application during complex procedures. neuro42’s portable system aims to address these limitations by offering real-time imaging and guidance during neurosurgical interventions.

The Impact of Innovation

When asked about her motivation to establish neuro42, Batra emphasizes her passion for solving complex medical problems. “Our mission is to revolutionize MRI technology by integrating artificial intelligence and robotics, creating a portable, point-of-care scanner that will enable physicians to access live imaging during neurosurgical interventions,” she explains. “This technology will help doctors achieve better outcomes and provide patients with the most advanced solutions available.”

The company’s approach offers several significant advantages. The portable nature of neuro42’s system contrasts sharply with traditional, bulky MRI machines, making it easier to use in various clinical settings. The integration of AI and robotics further enhances the system’s precision, allowing for more accurate diagnostics and interventions. For instance, the technology can be used intraoperatively to confirm brain tumor resections or guide brain biopsies, offering an additional layer of certainty and peace of mind for patients and their families.

Advancing the Frontier of MedTech

neuro42’s focus on futuristic technologies is evident in its commitment to advancing MRI methodology, diagnosis, and treatment outcomes. The company’s low-field MRI scanner, combined with robotics and AI, provides flexibility and adaptability for precise interventions. “In the realm of brain imaging, accuracy is paramount,” Batra notes. “Our goal is to offer a more affordable and effective solution compared to traditional MRI systems, with the added benefits of portability and advanced technology.”

The company’s dedication to innovation is matched by its commitment to making its technology widely accessible. Currently, neuro42 is focused on conducting clinical scans to gather data and refine its processes. The next major milestone is obtaining FDA clearance, after which the company aims to deploy its technology across numerous facilities, furthering its mission to enhance patient care.

Looking Ahead: The Future of neuro42

Batra’s vision for neuro42 is ambitious yet achievable. “We envision neuro42 becoming the new standard in MRI technology,” she says. “Our technology offers clear advantages to physicians and will significantly improve patient experiences. By providing cutting-edge tools that enable accurate diagnoses and better treatment outcomes, we are committed to saving lives and advancing brain health.”

The company’s future plans include expanding its technology’s reach and impact, continuing to innovate and adapt to the evolving needs of the medical field. Batra’s leadership and the dedicated team at neuro42 are poised to drive these efforts forward, ensuring that their pioneering solutions make a meaningful difference in the lives of patients and healthcare providers alike.

A Grateful Team and a Shared Vision

In closing, Batra reflects on the collaborative spirit that drives neuro42’s success. “I want to acknowledge our incredible team at neuro42,” she says. “Their dedication and passion for excellence are the backbone of our company. Every day, I am inspired by their commitment to bringing our technology to those who need it most. It’s a privilege to work with such a talented group of professionals who share a common goal of improving patient outcomes through innovation.”

neuro42, Inc. exemplifies the transformative potential of MedTech when driven by visionary leadership and a commitment to addressing pressing healthcare challenges. With its innovative approach to neuroimaging and intervention, the company is set to redefine the landscape of brain health and medical technology, offering hope and improved outcomes for patients across the United States. 

Abhita Batra, Co-Founder and Chief Strategy Officer

“The reasoning behind the creation of neuro42 was our observation of the increasingly high number of neurological conditions that occur each year and our desire to provide a better technological alternative for physicians and patients alike.”